Clinical Significance of Peripheral blood EB Virus Detection in NK/T Cell Lymphoma Patients / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To explore the clinical significance of peripheral blood EB virus detection in NK/T cell lymphoma patients.</p><p><b>METHODS</b>The positive rate of EB virus and EBV-DNA in 85 cases of NK/T cell lymphoma was assayed; the correlation of positive rate of EB virus with clinical staging, short-term and long-term prognosis was analyzed.</p><p><b>RESULTS</b>The positive rate of EB virus in NK/T cell lymphoma was high (80.00%). The EBV-DNA copy number in peripheral blood leukocytes was higher than that in peripheral plasma (P<0.05), but there was no significant difference in EBV-DNA level between peripheral leukocytes and serum (P>0.05). The I-II stages ratio of patients in EBVgroup was significantly lower than that in EBVgroup. The CR rate and ORR in EBVgroup was significantly lower than those in EBVgroup, the 3 year OS rate and 3 year DFR in EBVgroup also was significantly lower than those in EBVgroup.</p><p><b>CONCLUSION</b>The detection of periphera blood EBV may be used as an reference indicator for anxiliary diagnosis of NK/T cell lymphoma and evaluation of prognosis for patients, thus possessing a certain value for clinical application.</p>

Analysis of bortezomib treatment efficacy and adverse reactions for patients with follicular lymphoma / 中国实验血液学杂志

<p><b>OBJECTIVE</b>This study was aimed to investigate the therapeutic efficacy and safety of bortezomib in the treatment of follicular lymphoma patients.</p><p><b>METHODS</b>According to treatment methods, the 56 follicular lymphoma patients were divided into 2 groups: CHOP group (26 cases) and bortezomib group (30 cases). The patients in CHOP group received the CHOP chemotherapy regimens (cyclophosphamide+ epirubicin+vincristine+prednisolone), the patients in bortezomib group received bortezomib based on CHOP. The clinical curative effect and adverse reaction between the two groups were compared.</p><p><b>RESULTS</b>The short-term efficacy of bortezomib group showed significantly better than that in CHOP group (P < 0.05), the total efficiency in bortezomib group (80%) was significantly higher than that in CHOP group (53.85%) (P < 0.05). The progression free survival of the patients in the bortezomib group was statistically longer than that in the CHOP group (10 months vs 6 months) (P = 0.013). There was no significant differences in the overall survival mediam survival time between these two groups (10 months vs 11 months)(P = 0.107). The occurrence of adverse reactions in the two groups was no significant different (P > 0.05).</p><p><b>CONCLUSION</b>Bortezomib combined with CHOP chemotherapy can obviously prolong the progression free survival of patients, and improve the total efficiency without increase of adverse reaction. The benefit to overall survival needs to further extend follow-up observation.</p>

Clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma / 中国实验血液学杂志

<p><b>OBJECTIVE</b>This study was aimed to investigate the clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma (PTCL).</p><p><b>METHODS</b>Twenty-one patients with peripheral T-cell lymphoma were selected as control group, which were received CHOP; twenty-nine patients with peripheral T-cell lymphoma were selected as treatment group, which were received Hyper-CVAD. Clinical efficacy were observed after treatment.</p><p><b>RESULTS</b>In control group 6 patients achieved complete remission(CR), 4 patients achieved partial remission(PR), the total response rate of control group was 47.6%; in treatment group 15 patients achieved CR, 7 patients achieved PR, the total response rate of treatment group was 75.9%, and the total response rate of treatment group was significantly higher than that of control group. The incidence rates of cardiac dysfunction, peripheral neuropathy, anaemia and leucopenia between the two groups had no significant difference. The average progress free survival (PFS) of treatment group was 26.106 months, which was significantly higher than that of control group.</p><p><b>CONCLUSION</b>The clinical efficacy of dexamethasone, methotrexate combined with cyclophosphamide for treatment of patients with peripheral T-cell lymphoma has been confirmed to be satisfactory and it may be used in clinic.</p>

Clinical Efficacy of Radiotherapy Combined with Chemotherapy for Primary Mediastinal Large B-cell Lymphoma / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To explore the clinical efficacy of radiotherapy combined with chemotherapy for patients with primary mediastinal large B-cell lymphoma(PMLBCL).</p><p><b>METHODS</b>A total of 34 cases of PMLBCL were treated by radiotherapy combined with chemotherapy(radio-chemotherapy group), 28 cases of PMLBCL were treated by chemotherapy alone (single chemotherapy group as control). The clinical efficacy, side effects, long-term survival of the two group patients were compared.</p><p><b>RESULTS</b>The overall remission(OR) in the radio-chemotherapy group were higher than that in single chemotherapy group (P<0.05); the blood toxicity reaction, mucositis, radiation dermatitis in radio-chemotherapy group were higher than those in single chemotherapy group (P<0.05); the progress free survival(PFS) for 1 year in radio-chemotherapy group was higher than that in the single chemotherapy group (P<0.05), the local control (LC), PFS for 3 years in the radio-chemotherapy group were higher than those in the single chemotherapy group (P<0.05), the LC, OS, PFS for 5 years in the radio-chemotherapy group were higher than those in the single chemotherapy group (P<0.05).</p><p><b>CONCLUSION</b>The radiotherapy combined with chemotherapy has good clinical efficacy for patients with primary mediastinal large B-cell lymphoma, it has high rate of progression-free survival, it can be used as optimed scheme for treating PMLBCL, but the complications resulting from radio-chemotherapy should be prevented.</p>